The syndrome of chronic malabsorption, cholestasis, hypersensitivity to the drug or any other components contained in the capsule.
In studies of reproductive performance, no teratogenic and embryotoxic effect was observed in animals. In the absence of a teratogenic effect in animals, this effect should not be expected. However, due to the lack of clinical data, Xenical should not be given to pregnant women. Excretion of orlistat with breast milk has not been studied, so it should not be taken during breastfeeding.
Interactions with digoxin, metformin, phenytoin, warfarin, oral contraceptives, nifedipine, statins, and alcohol have not been reported.
It should be borne in mind the possibility of reducing the absorption of vitamins A, D, E, K, and beta-carotene.
Reducing the body weight during treatment with Xenical can improve the compensation of metabolism in diabetic patients and require a reduction in the dose of oral hypoglycemic drugs.
No cases of overdose of orlistat are described. In clinical studies in individuals with normal body weight and obese patients, taking single doses of 800 mg or repeatedly taking the drug 400 mg 3 times daily for 15 days was not accompanied by the appearance of significant adverse events. In addition, patients with obesity have experience of using orlistat 240 mg 3 times a day for six months.
In case of a severe overdose of orlistat, it is recommended to observe the patient within 24 hours. According to studies in humans and animals, any systemic effect that could be associated with the lipase-inhibiting properties of orlistat should be quickly reversible.